Diamyd Medical proceeds with initiation of Type 1 Diabetes Phase III trial in Europe

Diamyd Medical proceeds with the initiation of the Phase III trial DIAGNODE-3 in Europe with the Diamyd[®] diabetes vaccine. Results from in-depth analyses of the manufacturing process have shown no risk associated with a previously suspected contamination. The first patients are expected to be screened in March.“We are extremely happy and relieved to proceed with the initation of DIAGNODE-3 and I highly commend the team on their diligent efforts,” says Ulf Hannelius, CEO of Diamyd Medical. “We are now continuing at full speed and expect to screen the first patients in DIAGNODE-3 next month.